NIH's Therapeutics for Rare and Neglected Disease (TRND) program has announced its second solicitation for collaborative projects. The due date for applications is April 26, 2011. Details and forms can be found at the TRND website and ProposalCentral.
TRND is intended to stimulate research collaborations between intramural NIH drug development scientists and research partners such as academic laboratories, non-profit organizations, and pharmaceutical and biotechnology companies working on rare and neglected diseases. Through TRND, research partners who have promising leads or disease/target knowledge are afforded access to the expertise and resources they need to develop their leads or targets to a point where private companies would be interested in getting the products to market.
Currently, TRND develops small molecule, therapeutic antibody, protein, and stem cell therapeutics but does not support the development of vaccine, gene therapy, animal models, or diagnostics. A flyer about TRND is available at http://rarediseases.info.nih.gov/files/TRND_flyer_2010.pdf
This month, the TRND team is conducting informational sessions in five cities (Philadelphia, Irvine, San Diego, Boston, and New York). Each session includes a 45-minute presentation followed by a one-hour question and answer period. Anyone involved in the discovery or development of therapeutics for rare or neglected diseases is encouraged to attend to learn about the progress of the TRND program, how TRND collaborations operate, and how to submit an application to work with TRND.